Tsingke Biotech Showcases Innovative Solutions for Cancer Research at AACR 2025
Tsingke Biotech Showcases Innovative Solutions for Cancer Research at AACR 2025
In April 2025, Tsingke Biotech made a significant impact at the AACR Annual Meeting held in Chicago, Illinois. As a pivotal event in the world of oncology research, the meeting brought together leading experts from academia and industry to discuss the latest advancements in cancer diagnostics and therapeutics. Tsingke, with its booth (#3255), attracted considerable attention by unveiling its comprehensive synthesis and expression service portfolio tailored for cancer research.
Highlighting Key Offerings in Oncology Research
Tsingke’s dedication to supporting groundbreaking work in oncology was evident through its vast array of services. These offerings are designed to assist researchers from the initial stages of discovery through to preclinical development, ensuring that researchers have access to essential resources at every step. Key highlights of Tsingke’s product portfolio featured:
- - High-Throughput Nucleic Acid Synthesis: This includes custom DNA and RNA oligonucleotides, as well as complex modifications such as LNA or phosphorothioate, which are crucial for advanced research applications. Notably, Tsingke provides qPCR and NGS-grade primers and probes for a range of research requirements.
- - mRNA Synthesis: Tsingke supports researchers by offering IVT template synthesis with necessary modifications for high-purity enzymes, capping reagents, and modified nucleotides. This facilitates LNP (lipid nanoparticle) formulation workflows—a critical component in developing mRNA therapeutics.
- - Protein Expression Tools: With services including gene synthesis and vector construction, Tsingke provides rapid-expression services in HEK293 and CHO systems, which are vital for the production of therapeutic proteins and antibodies. This enables researchers to bring their therapeutic ideas into actual production swiftly.
- - Custom R&D Support for Novel Therapies: Tsingke offers sgRNA libraries and gene editing tools, alongside RNAi constructs, supporting researchers in novel therapeutic developments and enhancing the search for new cancer treatments.
Advancing Cancer Research Through Collaboration
Tsingke Biotech positions itself as a critical partner for biotech firms, CDMOs, and academic institutions seeking a comprehensive synthesis platform. By merging molecular design, synthesis, expression, and functional validation, Tsingke aids in expediting the process from laboratory research to patient care. In a field where speed and precision are essential, Tsingke's innovative solutions play a vital role in transforming the future of cancer treatments.
The commitment to fostering innovation within the oncology sector was clear at AACR 2025, where collaboration and forward-thinking were emphasized. Tsingke's presence not only showcased their technologies but also highlighted their role in driving the industry forward through persistent dedication to advancements in cancer research.
For those interested in learning more about Tsingke's offerings or discussing custom solutions tailored to their specific research needs, they are encouraged to reach out via email at [email protected] or visit their official website at www.tsingke.com.
As the landscape of cancer research continues to evolve, Tsingke Biotech is positioned as a key player in this critical field, dedicated to advancing methodologies that save lives.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.